Abstract: The present invention is intended to provide therapeutic/prophylactic agents and diagnostic for digestive diseases, etc.

Abstract: G Protein-coupled receptor proteins originating in the vicinity of rat brain stem and human brain or salts thereof, or peptide fragments thereof or amides, esters or salts of the same; ligands thereto; a method/kit for screening compounds capable of altering the binding properties of the ligands to the G protein-coupled receptor proteins; the compounds or salts thereof obtained by the above screening; antibodies against the G protein-coupled receptor proteins, etc.

Abstract: The present invention provides a human-derived protein or a salt thereof, a DNA encoding the same, a method for determination of ligand to the protein, a screening method/kits for a compound or its salt that alters a binding property between ligand and the protein, and the like. The human-derived protein or a DNA encoding the same of the present invention can be used in (1) determination of ligand to the protein of the present invention, (2) a prophylactic/therapeutic agent for diseases associated with dysfunction of the protein of the present invention, (3) a screening of a compound (agonist, antagonist, etc.) that alters a binding property between the protein and the ligand of the present invention, and the like.

Abstract: The present invention provides a novel G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 5 or salts thereof, and a polynucleotide encoding the same. The present invention also provides a use such as pharmaceuticals, etc.

Abstract: The present invention provides a novel G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 5 or salts thereof, and a polynucleotide encoding the same. The present invention also provides a use such as pharmaceuticals, etc.

Abstract: The present invention intends to provide a novel protein useful for a screening of agonists/antagonists. Specifically, the present invention provides rat- and mouse-derived protein or its salt, DNA encoding the protein, a determination method of ligand to the protein, a screening method and a screening kit for a compound that alters a binding property between ligand and the protein, a compound or its salt obtainable by the screening, and the like.

Abstract: This invention relates to glutamine:fructose-6-phosphate amidotransferase, or its partial peptide or a salt thereof; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein; a pharmaceutical composition comprising the protein, its partial peptide or a salt thereof; and an antibody against the protein or its partial peptide. The protein, its partial peptide or a salt thereof, and the DNA are useful for a prophylactic or therapeutic agent for hypoglycemia. The antibody can be used in the assay of the protein, its partial peptide or a salt thereof. The protein, its partial peptide or a salt thereof is useful as a reagent for the screening for candidate medical compounds.

Abstract: DNAs encoding human leukocyte-derived G protein-coupled receptor proteins or salts thereof are useful in: (1) determining ligands; (2) acquiring antibodies and antisera; (3) constructing a recombinant receptor protein expression system; (4) developing a receptor-bound assay system and screening candidate compounds for a drug using the expression system above; (5) designing drugs based on the comparison with ligand receptors having similar structures; (6) reagents in preparing probes, PCR primers, etc. for gene therapy; (7) constructing transgenic animals; (8) drugs such as gene preventives and remedies; etc.

Abstract: The present invention provides a novel G protein-coupled receptor protein or salts thereof, and a polynucleotide encoding the same, which is useful for screening agonist/antagonist and comprises the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1. It also provides a use such as pharmaceuticals.

Abstract: The present invention provides a novel G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 or salts thereof, and a polynucleotide encoding the same. The present invention also provides a use such as pharmaceuticals, etc.

Abstract: A novel G protein-conjugating receptor protein containing an amino acid sequence which is the same or substantially the same as the amino acid sequence represented by SEQ ID NO.1, or its salt; a polynucleotide encoding the same; and medicinal use, etc. thereof.

Abstract: This invention relates to a Fas ligand-like protein having an apotosis-inducing actibvity, etc. or its salt, a partial peptide of the protein or its salt; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein, a pharmaceutical composition comprising the protein, the partial peptide or its salt; and an antibody to the protein or the partial peptide. The protein, the partial peptide or its salt, and the DNA are useful as a prophylactic or therapeutic agent for cancer, viral infection, Helicobacter pylori infection, invasive staphylococcia, hepatitis, nephritis, bone disease, atherosclerosis or pain. The antibody can be used in assay of the protein, the partial peptide or its salt. The protein, the partial peptide or its salt is useful as a reagent for the screening for candidate medical compounds.

Abstract: The present invention provides a novel G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 or salts thereof, and a polynucleotide encoding the same, a use such as pharmaceuticals, etc.

Abstract: The present invention provides a novel G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 or salts thereof, and a polynucleotide encoding the same, a use such as pharmaceuticals, etc.

Abstract: The human leukocyte-derived G protein-coupled receptor protein, a nucleic acid encoding the same and its derivative are useful in determining a ligand (an antagonist) to the receptor protein of the present invention, as an agent for the prevention and/or treatment of diseases associated with the dysfunction of the G protein-coupled receptor protein, etc.

Abstract: This invention relates to glutamine:fructose-6-phosphate amidotransferase, or its partial peptide or a salt thereof; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein; a pharmaceutical composition comprising the protein, its partial peptide or a salt thereof; and an antibody against the protein or its partial peptide. The protein, its partial peptide or a salt thereof, and the DNA are useful for a prophylactic or therapeutic agent for hypoglycemia. The antibody can be used in the assay of the protein, its partial peptide or a salt thereof. The protein, its partial peptide or a salt thereof is useful as a reagent for the screening for candidate medical compounds.

Abstract: This invention is directed toward novel human and murine Fas ligand-like proteins having an apoptosis-inducing activity. Cloned cDNAs encoding human, mouse, and rat Fas ligand-like proteins were obtained from human liver, mouse embryo, and rat liver cDNA libraries. The cDNAs were expressed in a recombinant yeast (e.g., Pichia) expression system. The expressed proteins should prove useful in a number of biochemical and immunological applications.

Abstract: This invention relates to glutamine:fructose-6-phosphate amidotransferase, or its partial peptide or a salt thereof; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein; a pharmaceutical composition comprising the protein, its partial peptide or a salt thereof; and an antibody against the protein or its partial peptide. The protein, its partial peptide or a salt thereof, and the DNA are useful for a prophylactic or therapeutic agent for hypoglycemia. The antibody can be used in the assay of the protein, its partial peptide or a salt thereof. The protein, its partial peptide or a salt thereof is useful as a reagent for the screening for candidate medical compounds.

Abstract: This invention relates to a novel calpain having a proteolytic activity, its partial peptide or a salt either of them, a DNA coding for the protein, a recombinant vector comprising the DNA, a transformant carrying the recombinant vector, a process for producing the protein, a pharmaceutical composition comprising the DNA, an antibody against the protein, a method for screening for a compound which activates or inhibits a proteolytic activity of the protein, a kit for screening for the compound, and a compound which activates or inhibits a proteolytic activity of the protein which is identified by the screening method or the kit. The DNA coding for the protein of the present invention can be used as a therapeutic and prophylactic composition for a variety of diseases including tumor, cerebral apoplexy, cerebral infarction, subarachnoid hemorrhage, Alzheimer's disease, myodystrophy, cataract, ischemic heart disease, atherosclerosis, arthritis, and collagen disease.

Abstract: This invention relates to glutamine:fructose-6-phosphate amidotransferase, or its partial peptide or a salt thereof; a DNA coding for the protein; a recombinant vector; a transformant; a method for producing the protein; a pharmaceutical composition comprising the protein, its partial peptide or a salt thereof; and an antibody against the protein or its partial peptide. The protein, its partial peptide or a salt thereof, and the DNA are useful for a prophylactic or therapeutic agent for hypoglycemia. The antibody can be used in the assay of the protein, its partial peptide or a salt thereof. The protein, its partial peptide or a salt thereof is useful as a reagent for the screening for candidate medical compounds.